Upward revision of earnings guidance for the fiscal year ending March 2027. Business revenue increased by 8 million yen from the previous forecast, operating loss improved by 69 million yen, ordinary loss improved by 103 million yen, and net loss for the period improved by 94 million yen. The revision is based on shareholder returns and restraint in R&D spending, among other factors.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Ribomic Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4591-20261020-02.pdf","jir_short_summary":"Upward revision of earnings guidance for the fiscal year ending March 2027. Business revenue increased by 8 million yen from the previous forecast, operating loss improved by 69 million yen, ordinary loss improved by 103 million yen, and net loss for the period improved by 94 million yen. The revision is based on shareholder returns and restraint in R&D spending, among other factors.","jir_summary":"### Overview of the Revision to Earnings Guidance\nFollowing technical certification of the DDS aptamer technology within the drug discovery support business, estimates for preclinical trial costs and R&D expenses were revised, leading to an upward revision of the earnings guidance for the fiscal year ending March 2027. Revenue is expected to increase and profit-related items are generally expected to improve. The revised guidance reflects considerations such as foreign exchange and governmental subsidies and shows improvement compared to the prior-year period and the previously announced figures.\n\n### Key Points and Considerations Going Forward\nThe main causes of the revision include the execution of a technical evaluation agreement related to DDS aptamers, the trend in clinical costs related to RBM-006, and the impact of governmental subsidies. Actual R&D expenditure and the timing of new contract signings may cause future performance to fluctuate.","jir_financial_highlights":"Business Revenue: Previous Forecast A: 17 million yen (Revised Forecast B: 26 million yen)\nOperating Income: Previous Forecast A: -1,547 million yen (Revised Forecast B: -1,477 million yen)\nOrdinary Income: Previous Forecast A: -1,542 million yen (Revised Forecast B: -1,438 million yen)\nNet Income Attributable to Owners of Parent: Previous Forecast A: -1,543 million yen (Revised Forecast B: -1,449 million yen)\nNet Income Per Share: Previous Forecast A: -27.96 yen (Revised Forecast B: -25.64 yen)","jir_category":"","jir_hashtags":"#Ribomic, #EarningsGuidanceRevision, #DDSAptamer, #RBM-006","jir_key_figures":"Key Figure 1: Business Revenue 26 million yen (Previous A: 17 million yen)\nKey Figure 2: Net Income Attributable to Owners of Parent 1,449 million yen (Previous A: 1,543 million yen, difference -94 million yen)\nKey Figure 3: Net Income Per Share 25.64 yen (Previous A: 27.96 yen, difference -2.32 yen)","jir_meta_title":"Ribomic Inc. - Notice of Revision to Earnings Guidance\uff5cFiscal Year Ending March 2027","jir_meta_description":"Ribomic Inc. has upwardly revised its earnings guidance for the fiscal year ending March 2027. Overview of revised revenue and profit outlooks, background factors, and key considerations going forward.","jir_og_title":"Ribomic Inc.\uff5cNotice of Revision to Earnings Guidance","jir_og_description":"Due to a technical evaluation agreement for DDS aptamer technology and other factors, Ribomic Inc. has upwardly revised its earnings guidance for the fiscal year ending March 2027. Key figures and background explained.","jir_og_image_url":"\/assets\/og\/company-earnings_guidance.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-132858","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n